10x Genomics Statistics
Total Valuation
10x Genomics has a market cap or net worth of $8.56 billion. The enterprise value is $8.06 billion.
| Market Cap | 8.56B |
| Enterprise Value | 8.06B |
Important Dates
The last earnings date was Thursday, November 5, 2026, after market close.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
10x Genomics has 131.53 million shares outstanding. The number of shares has increased by 4.52% in one year.
| Current Share Class | 121.46M |
| Shares Outstanding | 131.53M |
| Shares Change (YoY) | +4.52% |
| Shares Change (QoQ) | +0.63% |
| Owned by Insiders (%) | 7.72% |
| Owned by Institutions (%) | 99.01% |
| Float | 119.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.83 |
| Forward PS | 12.43 |
| PB Ratio | 10.21 |
| P/TBV Ratio | 11.08 |
| P/FCF Ratio | 91.25 |
| P/OCF Ratio | 85.82 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 13.02 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 85.92 |
Financial Position
The company has a current ratio of 5.12, with a Debt / Equity ratio of 0.09.
| Current Ratio | 5.12 |
| Quick Ratio | 4.52 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.81 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -8.27% and return on invested capital (ROIC) is -4.60%.
| Return on Equity (ROE) | -8.27% |
| Return on Assets (ROA) | -3.93% |
| Return on Invested Capital (ROIC) | -4.60% |
| Return on Capital Employed (ROCE) | -7.12% |
| Weighted Average Cost of Capital (WACC) | 15.28% |
| Revenue Per Employee | $525,107 |
| Profits Per Employee | -$56,942 |
| Employee Count | 1,178 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 2.74 |
Taxes
In the past 12 months, 10x Genomics has paid $1.92 million in taxes.
| Income Tax | 1.92M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +326.56% in the last 52 weeks. The beta is 2.03, so 10x Genomics's price volatility has been higher than the market average.
| Beta (5Y) | 2.03 |
| 52-Week Price Change | +326.56% |
| 50-Day Moving Average | 74.02 |
| 200-Day Moving Average | 41.80 |
| Relative Strength Index (RSI) | 44.66 |
| Average Volume (20 Days) | 3,523,741 |
Short Selling Information
The latest short interest is 12.73 million, so 9.68% of the outstanding shares have been sold short.
| Short Interest | 12.73M |
| Short Previous Month | 15.37M |
| Short % of Shares Out | 9.68% |
| Short % of Float | 10.66% |
| Short Ratio (days to cover) | 3.09 |
Income Statement
In the last 12 months, 10x Genomics had revenue of $618.58 million and -$67.08 million in losses. Loss per share was -$0.52.
| Revenue | 618.58M |
| Gross Profit | 445.15M |
| Operating Income | -65.70M |
| Pretax Income | -65.16M |
| Net Income | -67.08M |
| EBITDA | -26.51M |
| EBIT | -65.70M |
| Loss Per Share | -$0.52 |
Balance Sheet
The company has $575.68 million in cash and $75.79 million in debt, with a net cash position of $499.89 million or $3.80 per share.
| Cash & Cash Equivalents | 575.68M |
| Total Debt | 75.79M |
| Net Cash | 499.89M |
| Net Cash Per Share | $3.80 |
| Equity (Book Value) | 838.04M |
| Book Value Per Share | 6.37 |
| Working Capital | 578.26M |
Cash Flow
In the last 12 months, operating cash flow was $99.70 million and capital expenditures -$5.93 million, giving a free cash flow of $93.77 million.
| Operating Cash Flow | 99.70M |
| Capital Expenditures | -5.93M |
| Depreciation & Amortization | 39.19M |
| Net Borrowing | n/a |
| Free Cash Flow | 93.77M |
| FCF Per Share | $0.71 |
Margins
Gross margin is 71.96%, with operating and profit margins of -10.62% and -10.84%.
| Gross Margin | 71.96% |
| Operating Margin | -10.62% |
| Pretax Margin | -10.53% |
| Profit Margin | -10.84% |
| EBITDA Margin | -4.29% |
| EBIT Margin | -10.62% |
| FCF Margin | 15.16% |
Dividends & Yields
10x Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.52% |
| Shareholder Yield | -4.52% |
| Earnings Yield | -0.80% |
| FCF Yield | 1.10% |
Analyst Forecast
The average price target for 10x Genomics is $68.14, which is 4.75% higher than the current price. The consensus rating is "Buy".
| Price Target | $68.14 |
| Price Target Difference | 4.75% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (3Y) | 6.12% |
| EPS Growth Forecast (3Y) | 44.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
10x Genomics has an Altman Z-Score of 9.25 and a Piotroski F-Score of 4.
| Altman Z-Score | 9.25 |
| Piotroski F-Score | 4 |